Hyperglycaemic Metabolic Complications of Ischemic Brain: Current therapeutics, anti-diabetics and stem cell therapy

CNS Neurol Disord Drug Targets. 2022 Jun 9. doi: 10.2174/1871527321666220609200852. Online ahead of print.ABSTRACTStroke is the leading cause of morbidity and mortality in diabetic patients. Diabetes alters endothelial function and disrupts brain pathways, resulting in a variety of systemic metabolic complications. Diabetics not only have impaired neurotransmission, but they also have progressive neurodegeneration, which leads to long-term neurological complications. Diabetes risk factors and physiology alter the frequency and severity of cardiovascular and cerebrovascular events, necessitating more hospitalizations. Stroke and diabetes have a mutually reinforcing relationship that worsens their outcomes. Diabetes has far-reaching systemic consequences for human physiology as a metabolic syndrome. As a result, diabetic stroke patients require dual-therapeutics with dual protection. Scientific researchers have made tremendous progress in diabetes-related stroke and its therapeutics over the last few decades. We have summarised diabetic brain and associated risk factors, co-morbidities, biomarkers and hyperglycemia associated neurovascular insult and cognitive demur. In addition to providing an overview of the effects of hyperglycaemia on brain physiology, this article aims to summarise the evidence from current glucose-lowering treatment, recent advances in stroke therapeutics as well as exploring stem cell therapy in the management of diabetes associated stroke.PMID:35692163 ...
Source: CNS and Neurological Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Source Type: research